NCT07216846 The Geriatric Emergency Department Pharmacologic Harm Prevention Project
| NCT ID | NCT07216846 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Florida Atlantic University |
| Condition | Fall |
| Study Type | INTERVENTIONAL |
| Enrollment | 1,000 participants |
| Start Date | 2026-01-01 |
| Primary Completion | 2027-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 1,000 participants in total. It began in 2026-01-01 with a primary completion date of 2027-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this project is to determine whether pharmacogenomic testing (using participants' DNA) can help optimize medication prescribing and reduce side effects in older adults taking five or more medications. The main questions it aims to answer are: * Can DNA-based prescribing reduce medication-related side effects, especially falls and fall-related injuries? * Does providing pharmacogenomic results to primary care physicians improve medication safety compared with usual care? Researchers will compare two groups: 1. DNA Care Pathway: Physicians receive patients' DNA results to guide prescribing. 2. Emergency Department Care Pathway: Physicians provide usual care; DNA results are shared only after study completion. Participants will: * Provide a cheek swab sample for DNA analysis (1 minute). * Receive monthly follow-up phone calls for 6 months to track falls, injuries, medication changes, and side effects. * Complete a fall and medication calendar. * Allow researchers to review primary care physician medical records for study outcomes. Approximately 1,000 participants will take part, with follow-up lasting about 6-7 months.
Eligibility Criteria
Inclusion Criteria: * Patients over the age of 65 with a ground level fall Exclusion Criteria: * hospice and/or DNR status.
Contact & Investigator
Richard Shih, MD
PRINCIPAL INVESTIGATOR
Florida Atlantic University
Frequently Asked Questions
Who can join the NCT07216846 clinical trial?
This trial is open to participants of all sexes, aged 65 Years or older, up to 110 Years, studying Fall. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07216846 currently recruiting?
Yes, NCT07216846 is actively recruiting participants. Contact the research team at rshih@health.fau.edu for enrollment information.
Where is the NCT07216846 trial being conducted?
This trial is being conducted at Delray Beach, United States.
Who is sponsoring the NCT07216846 clinical trial?
NCT07216846 is sponsored by Florida Atlantic University. The principal investigator is Richard Shih, MD at Florida Atlantic University. The trial plans to enroll 1,000 participants.